Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CARDIOVASCULAR DISEASE

Cardio-rheumatology: it’s time to collaborate

Nature Reviews Rheumatology volume 18, pages 247–248 (2022)Cite this article

Subjects

New EULAR recommendations offer useful guidance for improving cardiovascular health in patients with rheumatic and musculoskeletal disease. However, an interdisciplinary model of care is crucial to the optimal management of cardiovascular risk in these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cardio-rheumatology: a new model of shared care.

References

  1. Drosos, G. C. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-221733 (2022).

    Article  PubMed  Google Scholar 

  2. Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 76, 17–28 (2017).

    Article  CAS  Google Scholar 

  3. Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study. J. Rheumatol. 45, 378–384 (2018).

    Article  CAS  Google Scholar 

  4. Bartels, C. M. et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum. 63, 1221–1130 (2011).

    Article  Google Scholar 

  5. Navarro-Millan, I. et al. Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. BMC Rheumatol. 4, 26 (2020).

    Article  Google Scholar 

  6. Esmaeilbeigi, F. & Pope, J. E. Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice. Clin. Exp. Rheumatol. 36, 526–532 (2018).

    PubMed  Google Scholar 

  7. Okhovat, J. P. et al. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. J. Rheumatol. 44, 693–694 (2017).

    Article  Google Scholar 

  8. Rollefstad, S. et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann. Rheum. Dis. 72, 1968–1974 (2013).

    Article  CAS  Google Scholar 

  9. Nikpour, M., Gladman, D. D. & Urowitz, M. B. Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? Lupus 22, 1243–1250 (2013).

    Article  CAS  Google Scholar 

  10. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid Arthritis. N. Engl. J. Med. 386, 316–326 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Women’s College Hospital, Toronto, ON, Canada

    Lihi Eder & Paula Harvey

  2. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Lihi Eder & Paula Harvey

Authors
  1. Lihi Eder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula Harvey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lihi Eder.

Ethics declarations

Competing interests

L.E. declares that she has received research and educational grants from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB. P.H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eder, L., Harvey, P. Cardio-rheumatology: it’s time to collaborate. Nat Rev Rheumatol 18, 247–248 (2022). https://doi.org/10.1038/s41584-022-00774-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-022-00774-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing